Janux Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Janux Therapeutics (JANX).

Price Target Range — 11 Quarters

Analyst Consensus — 18 Analysts

14Buy

3Hold

1Sell

Consensus RatingBuy# Analysts18Avg. Consensus PT$47Upside to Avg. PT+136.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 24, 2026	Wolfe Research	Kalpit Patel	Upgrade	Peer Perform→Outperform	$23
Aug 7, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$58→$55
Jun 25, 2026	Truist Securities	Supawat Thongthip	Assumes	Buy	$80→$26
May 8, 2026	Piper Sandler	Kelsey Goodwin	PT Cut	Overweight	$30→$26
May 8, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$45→$36
May 8, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$68→$58
Apr 28, 2026	Jones Trading	Boris Peaker	PT Cut	Buy	$50→$28
Apr 20, 2026	Barclays	Etzer Darout	Downgrade	Overweight→Underweight	$29→$14
Apr 15, 2026	UBS	David Dai	Downgrade	Buy→Neutral	$57→$15
Feb 27, 2026	Cantor Fitzgerald	Josh Schimmer	PT Cut	Overweight	$150→$100
Feb 27, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$72→$68
Jan 20, 2026	Clear Street	Kaveri Pohlman	Downgrade	Buy→Hold	$32→$12
Jan 16, 2026	Piper Sandler	Kelsey Goodwin	PT Cut	Overweight	$42→$30
Dec 17, 2025	Barclays	Etzer Darout	PT Cut	Overweight	$48→$29
Dec 2, 2025	Stifel	Bradley Canino	PT Cut	Buy	$46→$38
Dec 2, 2025	Clear Street	Kaveri Pohlman	PT Cut	Buy	$80→$32
Dec 2, 2025	B of A Securities	Geoff Meacham	PT Cut	Buy	$58→$49
Dec 2, 2025	Cantor Fitzgerald	Josh Schimmer	PT Cut	Overweight	$200→$150
Dec 2, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$70→$45
Nov 25, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$70

More with Benzinga EdgeGet Access

Analyst Ratings News

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list. DRI, JANX, and more mentioned.

Avi Kapoor

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

Wolfe Research analyst Kalpit Patel upgrades Janux Therapeutics (NASDAQ:JANX) from Peer Perform to Outperform and announces $23 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $55.

Benzinga Newsdesk

PRO
Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26

Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ:JANX) with a Buy rating and lowers Price Target of $26.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $30 to $26.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36

Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and lowers the price target from $45 to $36.

Benzinga Newsdesk

Janux Therapeutics Inc

Janux Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PRO
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

PRO
Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26

PRO
Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36

People Also Watch

People Also Watch

Janux Therapeutics Inc

Janux Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

PROWolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PROGuggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

PROTruist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26

PROPiper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

PROWedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36

People Also Watch

People Also Watch

PRO
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target

PRO
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

PRO
Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26

PRO
Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

PRO
Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36